Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 48.50
Bid: 48.00
Ask: 49.00
Change: -3.00 (-5.83%)
Spread: 1.00 (2.083%)
Open: 50.00
High: 51.50
Low: 48.50
Prev. Close: 51.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

12 Apr 2018 13:20

RNS Number : 7534K
Cambridge Cognition Holdings PLC
12 April 2018
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Cambridge Cognition Holdings plc

 

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Type 1 Disclosure as per the Transparency Directive II Regulation

3. Details of person subject to the notification obligationiv

Name

Octopus Investments Nominees Limited

City and country of registered office (if applicable)

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

10.04.2018

6. Date on which issuer notified (DD/MM/YYYY):

11.04.2018

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

6.91%

N/A

6.91%

20,697,870

Position of previous notification (if

applicable)

10.78%

N/A

10.78%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00B8DV9647

 

1,429,771

 

6.91%

SUBTOTAL 8. A

1,429,771

6.91%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Octopus Capital Ltd

Octopus Investments Ltd

Octopus Investments Nominees Ltd

6.91%

10. In case of proxy voting, please identify:

Name of the proxy holder

N/A

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information N/A

 

Place of completion

33 Holborn, London, EC1N 2HT

Date of completion

11/04/2018

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLITMTTMBBBBBP
Date   Source Headline
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases
21st Jul 20227:00 amRNSTrading Update and Notice of Results
14th Jul 202211:06 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
30th Jun 20225:43 pmRNSHolding(s) in Company
8th Jun 20223:14 pmRNSResult of AGM
16th May 20224:35 pmRNSPosting of Annual Report & Notice of AGM
12th Apr 20227:00 amRNSResults for the year ended 31 December 2021
6th Apr 20227:00 amRNSSenior Management Appointments
31st Mar 20227:00 amRNSNotice of Results
29th Mar 20222:06 pmRNSSecond Price Monitoring Extn
29th Mar 20222:00 pmRNSPrice Monitoring Extension
28th Mar 20224:41 pmRNSSecond Price Monitoring Extn
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 20227:00 amRNS£1 million contract for pivotal autoimmune trial
24th Mar 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
4th Feb 202212:06 pmRNSHolding(s) in Company
2nd Feb 20227:00 amRNS£2.1 million contract
27th Jan 20227:00 amRNSTrading Update
10th Jan 20227:00 amRNSNew Major Pharma Client for Schizophrenia Trials
16th Dec 20217:00 amRNSElectronic Clinical Outcomes Assessment Contract
9th Dec 20217:00 amRNS£1.0m Schizophrenia clinical trial contract
22nd Nov 202111:50 amRNSHolding(s) in Company
16th Nov 20217:00 amRNSGrant of Options
2nd Nov 20217:00 amRNSDirectorate Change
26th Oct 20217:00 amRNSContract for pivotal schizophrenia clinical trial
6th Oct 202110:06 amRNSHolding(s) in Company
21st Sep 20217:00 amRNSInterim Results
3rd Aug 20217:00 amRNSTrading Update and Notice of Results
9th Jul 20214:41 pmRNSSecond Price Monitoring Extn
9th Jul 20214:35 pmRNSPrice Monitoring Extension
9th Jul 20217:00 amRNS£1 million contract for late phase cancer trial
1st Jul 20217:00 amRNSSpin-out of Monument Therapeutics
28th Jun 20214:40 pmRNSSecond Price Monitoring Extn
28th Jun 20214:36 pmRNSPrice Monitoring Extension
28th Jun 20212:06 pmRNSSecond Price Monitoring Extn
28th Jun 20212:00 pmRNSPrice Monitoring Extension
28th Jun 202111:05 amRNSSecond Price Monitoring Extn
28th Jun 202111:00 amRNSPrice Monitoring Extension
28th Jun 20217:00 amRNSNew £2.2 million contract
14th Jun 20217:00 amRNS£1.4m of contracts for digital health & wearables
11th Jun 20217:00 amRNSBrain Health Registry Cognitive Assessment Partner
3rd Jun 20213:58 pmRNSHolding(s) in Company
2nd Jun 20217:00 amRNSAppointment of Executive Director
27th May 202112:58 pmRNSResult of AGM and Board Changes
5th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
4th May 202111:52 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.